As a 19-year-old teen, Dr. Clay Siegall the President, CEO, and Chairman of the Board of Directors of Seattle Genetics saw his father put up a strong fight against cancer. When his father lost the war to cancer when Dr. Clay was 24 years old, Clay came out of the agony with a resolution and inspiration to better the limited state of oncological tools and facilities that left patients and practitioners alike with little options.
With this resolve in mind, Clay Siegall then proceeded to acquire his Ph.D. in Genetics from George Washington University. He went ahead to work with the National Cancer Center, National Institute of Health from 1988 to 1991 when he moved to the Bristol – Myers Squibs Pharmaceutical Research Institute. Agreeably it is in this institute that he learned the basics of running a pharmaceutical research company. By 1997 Dr. Siegall was ready to run an enterprise of his own, and he moved on to co-establish Seattle Genetics.
Clay has served Seattle Genetics in various capacities including the Executive Vice President and Chief Scientific Officer positions from 1997 to 2000 when he became the President, and as CEO since 2002. Aside from his responsibilities at Seattle Genetics, Dr. Clay also serves a director on the Board of Alder Biopharmaceuticals Inc., a position he has held since 2005. In 2014 Clay Siegall was appointed to the board of directors of Ultragenyx Pharmaceutical Inc. where he has been appraised with 100% board meetings attendance.
As an established academician, Dr. Siegall has seventy scientific publications under his name, a fete not so easy to accomplish for a man with a busy schedule. He has led Seattle Genetics through a series of scientific breakthroughs such as ADCETRIS, a brand now approved in more than 60 countries around the world. Many more products are under research or undergoing clinical trials, and pharmaceutical industry analysts are betting the investments to pay up soon.
As a shrewd business administrator, Siegall has had to sign multiple cooperation deals with other giants in the industry. Most of the deals made have seen the company performance rise astronomically while providing much needed time and capital to concentrate on research activities. Today, Seattle Genetics is market capitalized at $10 billion and prides itself of more than $350 million worth of annual sells. The rapid market valuation coupled with excellent performance have seen analysts speculate that Seattle Genetics is ripe for a takeover. All these have been possible under the able leadership of Clay.